Gut microbiome, alcohol-related liver disease, Denmark RCT
164 gut metagenome samples from adults with alcohol-related liver disease in Denmark, collected in a randomised controlled trial comparing the postbiotic ReFerm to a standard nutritional supplement (Fresubin) over 24 weeks. machine-written summary
164 samples · 328 runs · DK · Adult · 2024 · 9.58 Gbp / sample · cohort Alcohol-related liver disease disrupts bile acid h
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 492 sample values (country, subject id, timepoint) |
| ✓ Abstract / description | 164 sample values (collection date) |
| ✓ Full text | 984 sample values (antibiotic exposure, health condition, health condition detail, location locality, location region, location site) · PMC12214853 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Non-microbial dietary supplement (vitamins design randomized_controlled_trial · population liver_disease · ReFerm postbiotic fermented oats vs Fresubin, 24 weeks
“randomised controlled clinical trial” — bioproject.description (study level; per-sample arms are in the intervention column below)
longitudinal
42 of 43 people sampled more than once (163 samples; median 4, up to 4 per person) · follow-up median 5 mo (max 5 mo) · median interval between samples 5 mo (time from timepoint labels). Schedule stated by the source: “baseline, 4 weeks, 24 weeks (end of intervention), and after a 6-8 week wash-out” (time origin: intervention_start); stated follow-up 6 mo.
Each row is one person (1 shown of 42); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 156 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 164 | 100% | ||||
| country | 164 | 100% | 164 | |||
| health_condition | 164 | 100% | 164 | |||
| subject_id | 164 | 100% | 164 | |||
| antibiotic_exposure | 164 | 100% | 164 | |||
| collection_date | 164 | 100% | 164 | |||
| detailed_location | 164 | 100% | ||||
| health_condition_detail | 164 | 100% | 164 | |||
| location_locality | 164 | 100% | 164 | |||
| location_region | 164 | 100% | 164 | |||
| location_site | 164 | 100% | 164 | |||
| timepoint_label | 164 | 100% | 164 |
- The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial. 2025 PMID 40595534 PMC12214853 own_data
- Alcohol-related liver disease disrupts bile acid homeostasis and gut microbial bile acid metabolism. 2026 PMID 41935631 PMC13233754 unsure
Archive description
A 24 weeks prospective, randomised controlled clinical trial aiming to investigate if a postbiotic drink made of fermented oats, ReFerm, could alter the progression of liver disease compared to an active comparator, Fresubin. From March 2019 to January 2021, 56 patients were recruited and included in the study. Patients were allocated in a 1:1 ratio to either ReFerm or Fresubin treatment groups. Clinical investigations were conducted at baseline, 4 weeks, 24 weeks (end of intervention), and after a wash-out period of 6 to 8 weeks.
How this project entered the registry
Classified as human gut / stool / blood / tissue / internal fluids shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “Metagenomics of the gut microbiome of individuals”
- body site study.description · “the progression of liver disease compared to”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMEA115784827 | antibiotic_exposure | no | R3 | 0.70 | paper.fulltext.methods | antibiotic treatment in the prior 3 months |
| SAMEA115784827 | collection_date | 2019-03/2021-01 | R4 | 0.45 | ena.study_description | From March 2019 to January 2021, 56 patients |
| SAMEA115784827 | country | DK | R1 | 0.90 | sample.attr.geographic_location_country_and_or_sea | Denmark |
| SAMEA115784827 | health_condition | liver_disease | R3 | 0.70 | paper.fulltext.abstract | advanced, compensated, alcohol-related liver disease |
| SAMEA115784827 | health_condition_detail | advanced compensated alcohol-related liver disease (ALD) | R3 | 0.70 | paper.fulltext.abstract | advanced, compensated, alcohol-related liver disease |
| SAMEA115784827 | location_locality | Odense | R3 | 0.70 | paper.fulltext.methods | all investigations were conducted at Odense University Hospital |
| SAMEA115784827 | location_region | Region of Southern Denmark | R3 | 0.70 | paper.fulltext.methods | gastroenterology and hepatology departments across the Region of Southern Denmark |
| SAMEA115784827 | location_site | Odense University Hospital | R3 | 0.70 | paper.fulltext.methods | conducted at Odense University Hospital (Odense, Denmark) |
| SAMEA115784827 | subject_id | GALA-POSTBIO_PAHHV | R1 | 0.70 | sample.name_rule:title | GALA-POSTBIO_PAHHV-BL |
| SAMEA115784827 | timepoint_label | BL | R1 | 0.70 | sample.name_rule:title | GALA-POSTBIO_PAHHV-BL |
Sequencing
328 runs over 164 samples · mean 4.88 Gbp per run (median 2.52 Gbp, total 1,601.71 Gbp; 328 runs with a base count) · layout PAIRED 164, SINGLE 164 · platform ILLUMINA 328 · models NextSeq 2000 (328) · 62% of runs with a Sandpiper profile · first public 2024-11-12
Authors (47)
Hansen JK first · Israelsen M · Nishijima S · Stinson SE · Andersen P · Johansen S · Hansen CD · Brol MJ · Klein S · Schierwagen R · Uschner FE · Sulek K · Villesen IF · Lindvig KP · Thorhauge KH · Torp N · Jensen JM · Keller MI · Jensen GH · Detlefsen S · Leeming DJ · Stankevic E · Suvitaival T · Zawadzki A · Kuhn M · Jensen LJ · Karsdal M · Trebicka J · Israelsen H · Legido-Quigley C · Bork P · Arumugam M · Hansen T · Thiele M · Krag A last · de Zawadzki A · Schudoma C · Podlesny D · Fullam A · Kim CY · Niu L · Wretlind A · Akanni W · Hazenbrink D · Juel HB · Mann M · GALAXY & MicrobLiver consortia last
Downloads
PRJEB76668.csv.gz (5.7 KB) · parquet (77.3 KB) — all 164 samples, every field with route and confidence · PRJEB76668_determinations.csv.gz (11.0 KB) — 1,640 evidence rows